Summation
- Not only because we want to make the product commercially available in additional markets, but also due to the fact that we are going to rebrand the GoBack to BeBack.
- It is Bentley's intention to extend the global availability to all of the 80 markets in which the company is already active.
- Bentley, a global leader in minimally invasive medical devices for vascular treatments based in the Medical Valley of Hechingen, has acquired the rights of the GoBack catheter from Upstream Peripheral Technologies (Caesarea, Israel).
Bentley, a global leader in minimally invasive medical devices for vascular treatments based in the Medical Valley of Hechingen, has acquired the rights of the GoBack catheter from Upstream Peripheral Technologies (Caesarea, Israel).
This acquisition expands the company’s product portfolio, which is dedicated to improve the clinical outcomes of endovascular treatments, and because of this improving the patients’ quality of life.
Sebastian Büchert, Bentley’s CEO said:
“The acquisition of the GoBack catheter marks the start of inorganic growth for Bentley. We launched our first of six existing product families to the market in 2012 and have experienced significant growth since then. Now, only 10 years later, we are able to acquire this very innovative product. This strategic move further completes our product offering to hospitals and physicians to the benefit of our joint patients.”
The GoBack catheter will simplify to “cross” and/or “re-entry” lesions in the arteries, which are for example occluded by heavily calcified plaque or stenosis. Its unique feature is a curved nitinol needle that can be manipulated by the physician using the device handle. Thanks to its small profile, the device can even be used in the smaller arteries in the lower leg.
Dan Rottenberg, CEO of Upstream Peripheral Technologies added:
“Bentley acquiring the GoBack makes me feel proud. I am sure that with Bentley’s global footprint more physicians will have access to the catheter. Our vision is to save limbs and reduce the number of amputations. With Bentley’s strong network more patients will have access to such treatment.”
The GoBack catheter is CE marked and FDA cleared. The fact that the catheter also has FDA clearance will give Bentley the opportunity to explore the US market much quicker as initially planned. Launched in 2019, the device is now available in 23 countries. It is Bentley’s intention to extend the global availability to all of the 80 markets in which the company is already active.
Martijn Nugteren, Director Sales & Marketing, Bentley concluded:
“We will be really busy in the months ahead. Not only because we want to make the product commercially available in additional markets, but also due to the fact that we are going to rebrand the GoBack to BeBack. This is to make sure that our new product will be recognised as another leading product underneath Bentley’s brand umbrella.”
Currently produced in Israel and initially shipped from there, a production transfer to the Bentley production facility in Hechingen, Germany, will be completed by 2025.
